InVivoMAb anti-human CD47 | Bio X Cell BE0019-1-50MG product information

product summary

company name :

Bio X Cell

product type :

antibody

product name :

InVivoMAb anti-human CD47

catalog :

BE0019-1-50MG

quantity :

50 mg

price :

1,966.00 USD

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

MB23G2 (HB220)

reactivity :

human, mouse

application :

flow cytometry, blocking or activating experiments

more info or order :

Bio X Cell product webpage

citations: 10

Published Application/Species/Sample/Dilution	Reference
blocking or activating experiments; mouse; ; fig 1c	Theruvath J, Ménard M, Smith B, Linde M, Coles G, Dalton G, et al. Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. Nat Med. 2022;28:333-344 pubmed publisher
blocking or activating experiments; human; loading ...; fig 3a flow cytometry; human; loading ...; fig 1d	Chen J, Cao X, Li B, Zhao Z, Chen S, Lai S, et al. Warburg Effect Is a Cancer Immune Evasion Mechanism Against Macrophage Immunosurveillance. Front Immunol. 2020;11:621757 pubmed publisher
blocking or activating experiments; human; 1-25 ug/ml; loading ...; fig s2	von Roemeling C, Wang Y, Qie Y, Yuan H, Zhao H, Liu X, et al. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nat Commun. 2020;11:1508 pubmed publisher
	Kamerkar S, LeBleu V, Sugimoto H, Yang S, Ruivo C, Melo S, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017;546:498-503 pubmed publisher
	Gordon S, Maute R, Dulken B, Hutter G, George B, McCracken M, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545:495-499 pubmed publisher
	Lo J, Lau E, So F, Lu P, Chan V, Cheung V, et al. Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma. Liver Int. 2016;36:737-45 pubmed publisher
	Lo J, Lau E, Ching R, Cheng B, Ma M, Ng I, et al. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice. Hepatology. 2015;62:534-45 pubmed publisher
	Xiao Z, Chung H, Banan B, Manning P, Ott K, Lin S, et al. Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma. Cancer Lett. 2015;360:302-9 pubmed publisher
	Lee T, Cheung V, Lu P, Lau E, Ma S, Tang K, et al. Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology. 2014;60:179-91 pubmed publisher
	Tseng D, Volkmer J, Willingham S, Contreras Trujillo H, Fathman J, Fernhoff N, et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci U S A. 2013;110:11103-8 pubmed publisher

product information

Catalog Number :

BE0019-1-50MG

Product Name :

InVivoMAb anti-human CD47

Host :

Mouse

Clonality :

Monoclonal

Label/Conjugation :

Antigen Modification :

Category :

Antibody

Size :

50 mg

Regular Price :

$3,024.00

Academic Price :

1,966.00 USD

Clone Name :

MB23G2 (HB220)

Isotype :

B6.H12

Immunogen :

Intact CD47 purified from placenta

Reactivity :

Human

Concentration/Amount :

Lot specific,typically between 4-11 mg/ml

Reported Applications :

in vitro CD47 neutralization, in vivo CD47 neutralization in human tumor xenograft models or humanized mice, Flow cytometry

Recommended Storage Conditions :

The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.

more info or order :

Bio X Cell product webpage